NASDAQ:ADMA - ADMA Biologics, Inc.
$4.62
 $-0.06
-1.28%
4:00PM EDT
2019-04-18
ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  ADMA     avg for
industry  
  avg for
sector  
42 stocks weight:  0. 94   203. 85   241. 91  
42 stocks rank:  3. 36 K 1. 44 K 1. 05 K
# analyst opinions:  7. 00   14. 51   13. 97  
mean recommendation:  1. 90   2. 09   2. 01  

quick ratio:  2. 51   5. 27   1. 81  
current ratio:  4. 63   5. 62   2. 25  

target price low:  11. 00   84. 80   115. 21  
target price avg:  12. 79   111. 51   137. 51  
target price high:  5. 09   135. 81   157. 84  
1-yr high:  6. 85   114. 23   138. 78  
last close:  4. 62   87. 66   116. 69  
50-day avg:  4. 12   95. 54   123. 44  
200-day avg:  4. 77   94. 25   121. 11  
1-yr low:  2. 17   72. 78   98. 34  
volume:  613. 47 K 4. 11 M 8. 07 M
50-day avg volume:  1. 29 M 2. 76 M 5. 02 M
200-day avg volume:  525. 14 K 2. 92 M 4. 59 M

1-day return:  -1. 28 % -0. 41 % 0. 07 %
this week return:  -6. 29 % -5. 74 % -4. 11 %
12-wk return:  43. 48 % 1. 61 % -0. 05 %
52-wk return:  -8. 77 % 3. 12 % 8. 78 %

enterprise value (EV):  232. 86 M 48. 94 B 114. 64 B
market cap:  214. 15 M 43. 07 B 104. 73 B
EBITDA:  -57. 44 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -4. 05   4. 22   12. 73  
enterprise/revenue (EV/R):  13. 71   63. 17   12. 84  
total revenue:  16. 99 M 10. 62 B 38. 47 B
total debt:  41. 46 M 12. 24 B 16. 73 B
debt/equity:  209. 73   46. 71   89. 62  
net income (common):  -65. 74 M 2. 20 B 4. 20 B

shares outstanding:  46. 35 M 571. 70 M 1. 24 B
shares:  15. 08 M 571. 81 M 1. 23 B
shares short:  3. 15 M 10. 17 M 13. 00 M
shares short prior month:  2. 42 M 9. 54 M 17. 33 M
short ratio:  5. 38   5. 41   3. 28  
short % of float:  15. 60 % 5. 45 % 2. 38 %
total cash/share:  0. 49   11. 14   9. 33  
total cash:  22. 75 M 6. 71 B 7. 15 B
free cash flow:  -39. 44 M 3. 58 B 2. 96 B
operating cash flow:  -62. 68 M 4. 15 B 4. 30 B

book value:  0. 43   12. 78   26. 92  
price/book:  10. 82   3. 06   -1. 74  
gross profits:  -25. 21 M 8. 04 B 34. 86 B
operating margins:  -354. 95 % -725. 35 % -89. 04 %
EBITDA margins:  0. 00 % 10. 94 % 22. 51 %
profit margins:  0. 00 % 7. 81 % 10. 57 %
gross margins:  -148. 42 % 37. 08 % 55. 70 %

1-yr max volatility:  -45. 61 % --- ---
1-yr mean volatility:  0. 13 % 0. 03 % 0. 04 %

1-yr EPS:  -1. 46   2. 40   4. 10  
forward EPS:  -0. 59   3. 97   7. 13  
P/E:  -3. 18   13. 63   22. 72  
forward P/E:  -7. 83   -15. 95   13. 99  
PE/G:  0. 17   -1. 65   -1. 32  
growth:  -18. 90 % 127. 12 % 29. 61 %
earnings high:  -0. 24   1. 00   1. 66  
earnings avg:  -0. 32   0. 77   1. 53  
earnings low:  -0. 38   0. 50   1. 39  
revenue high:  4. 79 M 2. 68 B 10. 78 B
revenue avg:  3. 22 M 2. 59 B 10. 57 B
revenue low:  2. 50 M 2. 49 B 10. 36 B
return on assets:  -38. 27 % -2. 75 % 4. 55 %
return on equity:  -218. 77 % -18. 45 % 5. 46 %
revenue growth:  -18. 90 % 92. 86 % 18. 96 %
revenue/share:  0. 38   13. 29   55. 46  

beta (1yr vs S&P500):  0. 99   1. 25   0. 93  
sharpe (1yr):  0. 40   0. 37   0. 70  

held % insiders:  25. 50 % 6. 39 % 3. 38 %
held % institutions:  57. 51 % 78. 14 % 68. 52 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-21 : ADMA
.    + 0.694 =         0.694 :: INITIAL WEIGHT
.    + 33.89 =        34.584 :: spline projection addition
.    x 1.431 =        49.505 :: industry recommendation factor
.    x 2.331 =       115.418 :: symbol recommendation factor
.    x 1.217 =       140.465 :: EV/R factor
.    x 0.996 =       139.928 :: return on assets factor
.    x 0.978 =       136.867 :: return on equity factor
.    x 0.998 =       136.608 :: revenue growth factor
.    x 2.823 =       385.578 :: current ratio factor
.    x 1.289 =       497.184 :: quick ratio factor
.    x 1.089 =       541.423 :: short ratio factor
.    x 2.222 =      1203.286 :: price-to-book factor
.    x 1.852 =      2228.812 :: debt-to-equity factor
.    x 1.007 =      2243.505 :: 5-day avg > 200-day avg
.    x 1.166 =      2616.107 :: 5-day avg > 50-day avg
.    x 2.122 =      5550.496 :: P/E weight
.    x 1.562 =      8669.668 :: PE/G factor
.    x 1.633 =     14157.232 :: beta factor
.      x 0.4 =       5664.36 :: sharpe factor
.    x 2.347 =       13294.2 :: target low factor
.    x 1.443 =     19187.126 :: target mean factor
.    x 1.032 =      19801.03 :: target high factor
.     x 1.31 =     25937.129 :: industry 2-weeks return factor
.    x 0.986 =     25584.881 :: overall "drift" factor
.    x 0.998 =     25535.229 :: largest single-day jump factor
.     x 0.08 =       2033.06 :: low price factor
.      x 1.0 =       2032.73 :: factor hist industry gain for week 16
.   cubeRoot =        12.668 :: reduced to standardize
.   - 23.293 =         0.937 :: add/subtract for performance
.                      0.937 :: FINAL WEIGHT for NASDAQ:ADMA


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org